EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

SERPINB9 is associated with clinical improvement during aspirin therapy in aspirin-exacerbated respiratory disease

Piotr Szatkowski, Adam Stępień, Anna Gielicz, Adam Ćmiel, Hanna Plutecka, Joanna Szaleniec, Marek Sanak, Lucyna Mastalerz

Journal of Allergy and Clinical Immunology · 2026-08

DOI: 10.1016/j.jaci.2026.07.024 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Allergy and Clinical Immunology, 2026-08. Verfasst von Piotr Szatkowski und 7 weiteren Autor:innen. Beteiligte Einrichtung: 2nd Department of Internal Medicine, Jagiellonian University Medical College, Krakow, Poland. Die Arbeit nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Science Centre Poland.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

RATIONALE: Aspirin therapy after desensitization is a unique treatment option for patients with aspirin-exacerbated respiratory disease (AERD). However, biomarkers predicting response are lacking, and the effects of high-dose aspirin remain unclear. OBJECTIVES: We sought to determine clinical response to aspirin therapy after desensitization, identify predictive biomarkers, and compare aspirin-related molecular effects between AERD patients and healthy controls. METHODS: We conducted an 18-week, randomized, double-blind, placebo-controlled crossover trial of aspirin (600 mg/d) in patients with AERD (n = 14) and controls (n = 13). Each treatment arm lasted 8 weeks with a 2-week washout. Blood, induced sputum, nasal lavage, and urine samples were collected at 4 time points. Clinical outcomes, transcriptional profiles, cytology, and levels of eicosanoids, cytokines and chemokines were assessed. RESULTS: At baseline, AERD patients had higher blood eosinophils and elevated leukotriene E4 in plasma, nasal lavage, and urine, with reduced eoxin C4 in sputum supernatant and lower prostaglandin E2 and 12-hydroxyeicosatetraenoic acid in nasal lavage compared to controls. No differences in sputum gene expression were observed. SERPINB9 expression correlated with IL4RA in both groups and with PTGS2 in AERD. The disease of 8 patients (57.1%) responded to aspirin; however, the same number responded to placebo, with substantial overlap between treatments. Higher baseline SERPINB9 expression predicted response (odds ratio = 62.3; Padj = .03). After aspirin, SERPINB9 correlations with IL4RA and PTGS2 were lost in AERD but persisted in controls. No consistent molecular changes were observed after either treatment. CONCLUSION: Clinical improvement during aspirin therapy after desensitization was comparable to placebo. However, elevated baseline sputum SERPINB9 was associated with clinical improvement, highlighting potential as a candidate biomarker.

Schlagwörter

Stichwörter der Autor:innen

Aspirin-exacerbated respiratory diseaseSERPINB9, eicosanoidsaspirin therapy after desensitizationbiomarkers

Autor:innen und Institutionen

  • 2nd Department of Internal Medicine, Jagiellonian University Medical College, Krakow, Poland.
  • 2nd Department of Internal Medicine, Jagiellonian University Medical College, Krakow, Poland; Doctoral School of Medical and Health Sciences, Jagiellonian University, Krakow, Poland.
  • Faculty of Applied Mathematics, AGH University of Krakow, Krakow, Poland.
  • Department of Otolaryngology, Jagiellonian University Medical College, Krakow, Poland.
  • 2nd Department of Internal Medicine, Jagiellonian University Medical College, Krakow, Poland. Electronic address: lucyna.mastalerz@uj.edu.pl.

Förderung

  • National Science Centre Poland

Zitieren

APA

Szatkowski, P., Stępień, A., Gielicz, A., Ćmiel, A., Plutecka, H., Szaleniec, J., Sanak, M., & Mastalerz, L. (2026). SERPINB9 is associated with clinical improvement during aspirin therapy in aspirin-exacerbated respiratory disease. Journal of Allergy and Clinical Immunology. https://doi.org/10.1016/j.jaci.2026.07.024

Vancouver

Szatkowski P, Stępień A, Gielicz A, Ćmiel A, Plutecka H, Szaleniec J, et al. SERPINB9 is associated with clinical improvement during aspirin therapy in aspirin-exacerbated respiratory disease. Journal of Allergy and Clinical Immunology. 2026. doi:10.1016/j.jaci.2026.07.024

BibTeX
@article{Szatkowski2026,
  author = {Szatkowski, Piotr and Stępień, Adam and Gielicz, Anna and Ćmiel, Adam and Plutecka, Hanna and Szaleniec, Joanna and Sanak, Marek and Mastalerz, Lucyna},
  title = {SERPINB9 is associated with clinical improvement during aspirin therapy in aspirin-exacerbated respiratory disease},
  journal = {Journal of Allergy and Clinical Immunology},
  year = {2026},
  doi = {10.1016/j.jaci.2026.07.024}
}
Kostenlos starten →